Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ELOVL1 | Q9BW60 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10771375 | 0.94 | MAPK1 (0.53) | MAPK1ELOVL1KMT2AALDH1A1POLB | |
| Ammonia Solution, Strong SCHEMBL10656792 | 0.92 | MAPK1 (0.51) | MAPK1ELOVL1KMT2AALDH1A1POLB | |
| SCHEMBL21227788 | 0.92 | MAPK1 (0.51) | MAPK1ELOVL1POLBSLC9A1MPO | |
| SCHEMBL18250695 | 0.92 | MAPK1 (0.51) | MAPK1ELOVL1POLBSLC9A1MPO | |
| SCHEMBL22143644 | 0.82 | MAPK1 (0.58) | MAPK1ELOVL1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL25067562 | 0.79 | MAPK1 (0.44) | MAPK1ELOVL1KMT2ASLC9A1CYP1A2 | |
| SCHEMBL25871802 | 0.79 | MAPK1 (0.44) | MAPK1ELOVL1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL13212232 | 0.79 | SLC9A1 (0.41) | MAPK1KMT2AALDH1A1POLBNR1H3 | |
| SCHEMBL27028482 | 0.79 | MAPK1 (0.50) | MAPK1ELOVL1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL257500 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| US-9688696-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688696-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-02 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| CN-101918368-A | Method for improving the hydrolysis stability of ionic liquids | BASF SE | 2010-12-15 | — | — | CN | disclosed |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASE SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2229365-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-26 | — | — | US | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| WO-2009077452-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
| WO-2008148840-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216809-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, DLAT | MAPK1 2226/4885ELOVL1 3269/4885KMT2A 825/4885 |
| US-20170029440-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, PAOX, DGAT2 | MAPK1 2408/4885ELOVL1 3467/4885KMT2A 1091/4885 |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | MAPK1 2613/4885ELOVL1 313/4885KMT2A 1750/4885 |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | LIPA, IDE, CEL | MAPK1 4531/4885ELOVL1 509/4885KMT2A 1061/4885 |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | MAPK1 366/4885ELOVL1 4275/4885KMT2A 480/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | MAPK1 1475/4885ELOVL1 2686/4885KMT2A 2809/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MAPK1 224/4885ELOVL1 1951/4885KMT2A 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.